Semma Therapeutics racks up $114 mln Series B

Cambridge, Massachusetts-based Semma Therapeutics, a biotechnology company focused on developing new regenerative medicines, has secured $114 million in Series B financing. Eight Roads Ventures and Cowen Healthcare Investments led the round with participation from other investors that included MPM Capital, F-Prime Capital Partners, ARCH Venture Partners, Novartis, Medtronic, JDRF T1D Fund, ORI Healthcare Fund, Wu Capital, 6 Dimensions Capital and SinoPharm Capital. In conjunction with this financing, Semma has added Daniel Auerbach from Eight Roads and Kevin Raidy from Cowen to its board of directors.

ManagersNorth AmericaUSHealthcareBriefs